Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Forecasted to Post FY2024 Earnings of ($1.28) Per Share

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Equities researchers at Wedbush increased their FY2024 EPS estimates for Black Diamond Therapeutics in a research report issued on Tuesday, August 6th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.28) per share for the year, up from their previous forecast of ($1.29). Wedbush has a “Outperform” rating and a $16.00 price target on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.43) per share. Wedbush also issued estimates for Black Diamond Therapeutics’ Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.28) EPS and FY2028 earnings at $1.12 EPS.

BDTX has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Friday, June 7th. Piper Sandler reissued an “overweight” rating and issued a $12.00 target price on shares of Black Diamond Therapeutics in a research report on Wednesday, July 3rd. Finally, Raymond James initiated coverage on shares of Black Diamond Therapeutics in a report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 price target on the stock.

Black Diamond Therapeutics Stock Down 4.2 %

Shares of NASDAQ BDTX opened at $4.64 on Friday. Black Diamond Therapeutics has a 52-week low of $1.62 and a 52-week high of $7.66. The stock has a market capitalization of $261.01 million, a price-to-earnings ratio of -2.80 and a beta of 2.49. The stock’s fifty day simple moving average is $5.31 and its 200 day simple moving average is $5.07.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.09.

Institutional Investors Weigh In On Black Diamond Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC acquired a new position in shares of Black Diamond Therapeutics in the 1st quarter valued at about $82,000. Foundations Investment Advisors LLC increased its stake in Black Diamond Therapeutics by 17.7% in the 2nd quarter. Foundations Investment Advisors LLC now owns 113,550 shares of the company’s stock valued at $529,000 after buying an additional 17,050 shares during the period. Acadian Asset Management LLC boosted its stake in shares of Black Diamond Therapeutics by 13.8% during the 1st quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock valued at $864,000 after buying an additional 20,616 shares during the period. SG Americas Securities LLC purchased a new position in shares of Black Diamond Therapeutics during the 2nd quarter valued at $108,000. Finally, Jump Financial LLC increased its stake in shares of Black Diamond Therapeutics by 245.0% in the fourth quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock worth $109,000 after acquiring an additional 27,616 shares during the last quarter. 95.47% of the stock is currently owned by institutional investors and hedge funds.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.